Abstract: The well-known lapinized vaccine Chinese strain (also known as C-strain) against classical swine fever was jointly developed by National Control Institute of Veterinary Bio-products and Pharmaceuticals and Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences in China in the middle 1950s. The major contributors include Drs. Zhou Taichong, Yuan Qingzhi, Fang Shijie, Chen Lingfeng. In the past half a century, the vaccine was proved to be safe and immunogenic in pigs of essentially any age. It was of high efficacy. It provided immunized animals with broad-spectrum, sometimes lifelong, protection, which is contributed by cell-mediated immunity and humoral immunity, against essentially all genotypes or subgenotypes of the virus. The maternal antibodies derived from immunized sows can confer solid protection on their offspring from disease; however, they have been proved to inhibit the successful immunization of C-vaccine. The complete genome of C-strain, together with those of its parent strain and dozens of established and field strains, has been sequenced and annotated. Recently, the reverse genetics system of C-strain has been developed, resulting in several C-strain-derived candidate marker vaccines. Many countries manage to control or even eradicate CSF with the aid of C-strain vaccination. In spite of these efforts, the eradication of the disease worldwide remains a big challenge and needs a long way to go, and provably still resort to genetically modified C-strain. This paper reviews and prospects different aspects of the vaccine, which has stood the test of half a century.

Key words: Swine fever , Lapinized vaccine